Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRME
#2330
Prime Medicine, Inc. - Common Stock
3.5
5
USD
+4.41%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+4.41%
Monthly Change
+0.28%
6 month change
-4.05%
Year Change
+186.29%
Previous Close
3.4
0
Open
3.5
5
Low
3.5
5
High
3.5
5
Volume
67
Markets
US Stock Market
Healthcare
PRME
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2022
2023
2024
2025
Total assets
360.31 M
193.85 M
297.51 M
342.73 M
Total liabilities
44.04 M
60.78 M
144.36 M
221.87 M
Total equity
316.27 M
133.07 M
153.15 M
120.87 M
Total liabilities & shareholders' equities
360.31 M
193.85 M
297.51 M
342.73 M
Total debt
—
—
—
—
Net debt
—
—
—
—
Prime Medicine, Inc. - Common Stock
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
News
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Citizens reiterates Prime Medicine stock rating on PM359 pathway
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Prime Drink Group completes first closing of private placement
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond
Prime Drink Group announces private placement to raise up to $5 million
Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates